Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc.
- Market cap
- $55.37M
Your view on CGTX
Overview
What the company does, where it operates, and who runs it.
About Cognition Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Lisa Ricciardi
- Headquarters
- 2500 Westchester Avenue, Purchase, NY, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Lisa Ricciardi
- Headquarters
- 2500 Westchester Avenue, Purchase, NY, US
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD).
The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Cognition Therapeutics, Inc.. Starting points for Cognition Therapeutics, Inc.: EPS -$0.17, beta 1.80 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Cognition Therapeutics, Inc.. Trailing twelve-month EPS for Cognition Therapeutics, Inc. stands at -$0.17. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Cognition Therapeutics, Inc.. Cognition Therapeutics, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PRNAFAlterity Therapeutics Limited | Healthcare | OTC | $109.8M | ||
| PROKProKidney Corp. | Healthcare | NASDAQ | $349.7M | ||
| PROTProteonomix, Inc. | Healthcare | OTC | $791 | ||
| PRQRProQR Therapeutics N.V. | Healthcare | NASDAQ | $146.8M | ||
| PRRUFImmutep Limited | Healthcare | OTC | $368.0M | ||
| PRTAProthena Corporation plc | Healthcare | NASDAQ | $422.1M | ||
| PRTCYPureTech Health plc | Healthcare | OTC | — | ||
| PRVCFPreveCeutical Medical Inc. | Healthcare | OTC | $10.1M | ||
| PSYBFPsyBio Therapeutics Corp. | Healthcare | OTC | $1,275 | ||
| PTCHFPureTech Health plc | Healthcare | OTC | $410.4M | ||
| PTCTPTC Therapeutics, Inc. | Healthcare | NASDAQ | $4.7B | ||
| PTGXProtagonist Therapeutics, Inc. | Healthcare | NASDAQ | $7.9B | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Cognition Therapeutics, Inc., and how their positions are changing. At a $55.4M market value, institutional positions materially move Cognition Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Cognition Therapeutics, Inc. executives and directors. Shares of Cognition Therapeutics, Inc. have traded between $0.22 and $3.83 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Cognition Therapeutics, Inc.. Coverage tracks Cognition Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Cognition Therapeutics, Inc.